Nikola (OTC:NKLAQ) 주식

Nikola Corp is a technology innovator and integrator, working to develop inventive energy and transportation solutions. It works on a business model that enables customers and fleets to integrate next-generation truck technology, hydrogen fueling and charging infrastructure, and related maintenance. It operates in two business units: Truck and Energy. The Truck business unit and Energy business unit. The Truck business unit is engaged manufacturing and selling FCEV and BEV trucks that provide, environmentally friendly, cost effective solutions to the trucking sector. The Energy business unit is engaged in developing and constructing a network of hydrogen fueling stations to meet hydrogen fuel demand for the Company's customers.

Nikola Corp

UNIT

Uniti Group Stockholders Approve Proposed Merger With Windstream Holdings II, LLC; The Transaction Is Expected To Close In The Second Half Of 2025, Subject To The Receipt Of Certain Regulatory Approvals.

KANSAS CITY, Mo., April 02, 2025 (GLOBE NEWSWIRE) -- H&amp;R Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRB#NYSE">HRB</a>) today announced that the company's Board of Directors has unanimously elected Richard A. Johnson as the new Chairman of the Board, effective April 1, 2025. Johnson joined the H&amp;R Block Board of Directors in 2015 and is a member of the Audit and Compensation Committees. He succeeds Robert A. Gerard, who has served as Chairman since 2011.
In announcing the change, Gerard said, "Consistent with our commitment to Board refreshment and succession planning, the time has come for Dick to take over Board leadership as we transition to our next 5-year strategy for growth and transformation. Dick has been a great partner for the last 10 years and I'm delighted that he will continue to serve all of us at H&amp;R Block as Chairman of the Board."
"I'm honored to be H&amp;R Block's Chairman and to succeed Bob, who has led the Board and company to much success," Johnson said. "It is a privilege to serve the company that defines a category and helps millions of people each year. I look forward to continued success as we begin the next phase of H&amp;R Block's transformation."

News

Management

H&R Block Appoints Richard A. Johnson As Board Chairman Effective April 1, 2025

Earnings

CYCC

Cyclacel Pharmaceuticals Reports Q4 EPS Of $(0.33)

Prestige Wealth Announces Nasdaq Notification Regarding Minimum Bid Price Deficiency

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclearwateranalytics.com%2F%3Futm_medium%3Dthird-party%26utm_source%3Dpress-release%26utm_campaign%3Dbw-enfusion_election_date&amp;esheet=54232558&amp;newsitemid=20250402055366&amp;lan=en-US&amp;anchor=Clearwater+Analytics&amp;index=1&amp;md5=4259745238b944125d97a11b4825ea91">Clearwater Analytics</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>) ("Clearwater") and Enfusion, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENFN#NYSE">ENFN</a>) ("Enfusion") today announced that the deadline for Enfusion shareholders of record to elect the form of merger consideration (the "Merger Consideration") they wish to receive in connection with Clearwater's acquisition of Enfusion (the "Transaction") is 5:00 p.m. Eastern Time on April 16, 2025 (such deadline, as it may be extended, the "Election Deadline").
Enfusion shareholders who hold shares through a bank, broker or other nominee may be subject to an earlier election deadline and must carefully review and properly complete any election materials they received from their bank, broker or other nominee regarding how to make an election. The parties expect to close the Transaction on or about April 21, 2025, subject to the approval of the Transaction by Enfusion shareholders and the satisfaction or waiver of other customary closing conditions.
The election materials necessary for Enfusion shareholders of record to make an election as to the form of Merger Consideration they wish to receive have been sent to holders of record of Enfusion common stock as of March 20, 2025.
Enfusion shareholders of record wishing to make an election must deliver properly completed election materials to Computershare Trust Company, N.A. by the Election Deadline.
As previously disclosed, on January 10, 2025, Enfusion, Clearwater, Enfusion Ltd. LLC ("Enfusion OpCo"), Poseidon Acquirer, Inc., Poseidon Merger Sub I, Inc. and Poseidon Merger Sub II, LLC entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement and as further described in the election materials and in the parties' definitive proxy statement/prospectus dated March 20, 2025, as supplemented by Supplement No. 1 thereto dated March 31, 2025 (the "Proxy Statement/Prospectus"), at the effective time of the Transaction (the "Effective Time"), each Enfusion shareholder will be entitled to receive, for each (i) share of Class A common stock of Enfusion outstanding as of immediately prior to the Effective Time, (ii) restricted stock unit of Enfusion that is vested as of immediately prior to the Effective Time or that will vest as a result of the consummation of the Transaction and (iii) limited liability company unit of Enfusion OpCo outstanding as of immediately prior to the Effective Time, in each case subject to proration according to the terms of the Merger Agreement to the extent any election is oversubscribed:
&nbsp;
<ol>
<li>(i) cash in an amount equal to $5.85 and (ii) a number of shares of Class A common stock of Clearwater equal to the Per Share Parent Stock Amount (as defined below);</li>
<li>a number of shares of Class A common stock of Clearwater equal to the Exchange Ratio (as defined below); or</li>
<li>cash in an amount equal to the Aggregate Consideration Per Share (as defined below); and</li>
</ol>
in each case, cash in lieu of any fractional shares of Class A common stock of Clearwater that such shareholder would otherwise be entitled to receive. The value paid per share of Enfusion Class A common stock will be equalized such that the value of the Merger Consideration will be substantially the same, regardless of which form of Merger Consideration is elected.
The "Per Share Parent Stock Amount" will be determined by dividing $5.40 by the volume-weighted average price (such price, the "Final Parent Stock Price") of one share of Clearwater Class A common stock for the ten-trading day period ending on (and including) the second to last trading day prior to (but not including) the closing date of the Transaction (the "Closing Date"); provided that (x) if the Final Parent Stock Price is less than or equal to $25.0133, then the Per Share Parent Stock Amount will be deemed to be 0.2159 and (y) if the Final Parent Stock Price is greater than or equal to $30.5718, then the Per Share Parent Stock Amount will be deemed to be 0.1766. The "Aggregate Consideration Per Share" will be determined by dividing the Aggregate Consideration by the total number of Enfusion Class A common stock and restricted stock units and Enfusion OpCo limited liability company units eligible to receive Merger Consideration (collectively, the "Eligible Shares"). The "Aggregate Consideration" will be determined as the sum of (i) a number of shares of Clearwater Class A common stock equal to the product of (x) the Per Share Parent Stock Amount multiplied by (y) the total number of Eligible Shares multiplied by (z) the Final Parent Stock Price and (ii) the product of $5.85 multiplied by the total number of Eligible Shares. The "Exchange Ratio" will be determined by dividing the Aggregate Consideration Per Share by the Final Parent Stock Price.

CWAN

ENFN

Clearwater Analytics and Enfusion Releases Election Deadline Of 5PM EST On April 16, 2025 For Enfusion Shareholders To Elect Form Of Merger Consideration

Myers Industries CFO  Grant Fitz Resigns; Daniel Hoehn Named Interim CFO

Arq Names Jay Voncannon As Chief Financial Officer, Effective April 2, 2025

Hyperscale Data, Inc. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#AMEX">GPUS</a>) stock traded higher on Wednesday after the company announced its subsidiary, Sentium, mined an additional 56 Bitcoin from <a href="https://www.benzinga.com//node/44602852">January to March 2025</a>.
What To Know: The new 56 Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) mined this year brings the company&#8217;s total holdings to 3,061 since its inception in March 2021.
&#8220;The company is proud of the Sentinum team and the efficiency with which the mining operations are run. We believe it is important to update stockholders on our current and historical Bitcoin mining operations and of Sentinum&#8217;s accomplishments in the Bitcoin mining space,&#8221; stated William B. Horne, CEO of Hyperscale.
&#8220;The company has previously noted its intentions to relocate the majority of its Bitcoin mining operations concurrently with the buildout of its Michigan Data Center and will continue to update stockholders as this progresses.&#8221;
GPUS Price Action: Hyperscale shares closed 16.6% lower at $2.70, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
See Also: • <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44614272/nvidia-stock-is-down-nearly-20-ytd-whats-going-on">Nvidia Stock Is Down Nearly 20% YTD: What&#8217;s Going On?</a>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Movers

$BTC

GPUS

What's Going On With Hyperscale Shares Wednesday?

Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.13) by 38.46 percent. This is a 233.33 percent decrease over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $59.61 million which missed the analyst consensus estimate of $62.64 million by 4.83 percent. This is a 2.81 percent decrease over sales of $61.34 million the same period last year.

Earnings Beats

Earnings Misses

Franklin Covey Q2 2025 GAAP EPS $(0.08) Beats $(0.13) Estimate, Sales $59.61M Miss $62.64M Estimate

Politics

Trading Ideas

General

S&P 500 Futures, Crude Oil, Bitcoin Futures All Move Higher After President Trump Announces 10% Tariffs

DOWNERS GROVE, Ill., April 2, 2025 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4397351-1&amp;h=4221339429&amp;u=https%3A%2F%2Fwww.caldera.com%2F&amp;a=Caldera">Caldera</a>, part of <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4397351-1&amp;h=1533402104&amp;u=https%3A%2F%2Fwww.dovercorporation.com%2F&amp;a=Dover">Dover</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOV#NYSE">DOV</a>), today announced the release of PrimeCenter 4.0, a major update to its innovative production automation software designed to simplify job preparation and accelerate production workflows for digital printing companies of all sizes. This update introduces an expanded interface and automation features that allow users to prepare files for production in just a few clicks.
"PrimeCenter 4.0 is all about making job preparation faster and easier," said Céline Levy, Product Manager at Caldera. "By enhancing automation, simplifying navigation and introducing step-by-step guidance, we're helping businesses remove bottlenecks and focus on what really matters — getting their jobs ready for production. We've refined the user experience without altering the workflows our customers depend on, helping ensure a seamless transition to a more efficient way of working."
 &nbsp;

Caldera Launches PrimeCenter 4.0, Introduces Easier Way To Automate Digital Printing Job Preparation

Guidance

Penguin Solutions, Inc. - Ordinary Shares

PENG

Penguin Solutions Expects FY25 Net Sales Growth Of 17% YoY +/-3% (Prior View 	
15% YoY Growth +/-5%; Adj EPS Of $1.60 +/- $0.10 (Prior View $1.50 +/- $0.20), Est $1.58

TEL AVIV, Israel, April 2, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic diseases and GI oncological indications, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission (the 'SEC').
 &nbsp;

Biotech

GLMD

Galmed Pharmaceuticals Files Annual Report On Form 20-F For Fiscal Year Ended December 31, 2024

ICCC

ImmuCell Initiates Investigational Product Use Of Re-Tain

TSLA

President Trump Announces 25% Auto Tariffs

New Tariff Plan Is Combination Of Proposals For Universal Tariffs And Country-by-country Rates

Macro Economic Events

Economics

President Trump Says U.S. To Impose 10% Across-The-Board Tariffs On All Imports

RLI Transportation Partners With TruckerCloud To Provide RLI Transportation With Unified Telematic Insights Solutions

Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) has been one of the most volatile AI stocks this year. After surging nearly 400% in 2024, the stock has struggled in recent months, dropping 25% from its all-time high <a href="https://www.benzinga.com/quote/PLTR">reached in mid-February. </a>
What To Know: Palantir has benefited from growing demand for its AI-powered data analytics platforms, particularly among government agencies and large enterprises. The company's revenue growth remains strong, with management projecting a 36% increase in the first quarter. However, some analysts believe this estimate may be conservative, as Palantir has a track record of setting expectations lower to deliver consistent revenue beats.
Even with this growth, Palantir's stock price has been a point of concern. The stock currently trades at a price-to-sales (P/S) ratio of 77, a level that requires extreme revenue acceleration to justify. For comparison, most software companies trade between 10 and 20 times sales. At its current valuation, Palantir would need to triple its revenue annually to maintain its stock price, an unlikely scenario given its current growth trajectory.
Ai Outlook: The AI investment landscape is also shifting. While businesses continue to integrate AI solutions, spending trends are becoming more scrutinized. 
Investors who piled into Palantir during last year's AI boom are now questioning whether the company can sustain its momentum. If revenue growth falls short or macroeconomic headwinds intensify, Palantir's stock could see further downside.
Market Overview: Market-wide weakness in high-growth tech stocks has also weighed on Palantir. Other AI-related names, including C3.ai (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) and Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>), have seen similar pullbacks, reflecting broader concerns about valuations in the sector. While Palantir remains a leader in AI-driven analytics, its current stock price leaves little room for error.
The next few quarters may be crucial in determining whether Palantir can justify its high valuation. If the company continues to beat growth expectations and expand its commercial customer base, investor confidence may stabilize. However, if growth stalls or macroeconomic risks intensify, the stock could remain under pressure.
PLTR Price Action: Palantir shares closed up 3.27% at $87.45 at publication Wednesday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0402"><img loading="lazy" decoding="async" width="1024" height="536" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02154248/Screenshot-2025-04-02-at-15.42.13-1024x536.png" alt="" class="wp-image-854115" style="width:343px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02154248/Screenshot-2025-04-02-at-15.42.13-1024x536.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02154248/Screenshot-2025-04-02-at-15.42.13-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02154248/Screenshot-2025-04-02-at-15.42.13-768x402.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02154248/Screenshot-2025-04-02-at-15.42.13-1536x804.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02154248/Screenshot-2025-04-02-at-15.42.13.png 1544w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44613907/tariff-shock-incoming-as-trump-prepares-sweeping-trade-duties-what-traders-need-to-know">Trump&#8217;s &#8216;Liberation Day&#8217; Tariff Reveal Set For 4 PM: What&#8217;s At Stake</a></li>
</ul>
Photo: Shutterstock.

Tech

PLTR

SNOW

Palantir Stock Drops 25% YTD From Highs As Valuation Concerns Grow: What You Need To Know

<h2>to Debut EluPro&#x2122; at HRS 2025 — Experience the Difference Biology Makes</h2>

ELUT

Elutia To Debut Its EluPro Antibiotic-Eluting BioEnvelope At HRS Annual Meeting

Nikola

Comments

Nikola

뉴스

파트너 / 기고자

벤징가 글로벌